Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00073489 · ClinicalTrials.gov registry record · Phase 2

A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL)

A Phase 2 study of Chronic Lymphocytic Leukemia, sponsored by Astellas Pharma.

Completed
Registry status
Phase 2
Development phase
23
Enrollment target
15
Study locations

NCT00073489: Completed Phase 2 study of Chronic Lymphocytic Leukemia, sponsored by Astellas Pharma.

NCT00073489 is a Phase 2 study of Chronic Lymphocytic Leukemia that has completed, run by Astellas Pharma. The registered enrollment target is 23 participants, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (87% lower). The trial reports 15 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00073489, a Phase 2 study of Chronic Lymphocytic Leukemia, has completed, sponsored by Astellas Pharma.

COMPLETED
Registry status
Phase 2
Development phase
23 participants
Enrollment target
15
Study locations

Study Summary

The objectives of this study are to evaluate the safety and efficacy of OSI-461 in CLL patients.

Conditions Studied

Chronic Lymphocytic Leukemia

Interventions

  • DRUG OSI-461

Study Locations (15)

Texas

  • Southwest Regional Cancer Center - Austin
  • Hematology Oncology Associates of South Texas - San Antonio
  • Tyler Cancer Center - Tyler

Florida

  • Florida Oncology Associates - Jacksonville
  • Ocala Oncology Center - Ocala

Arizona

  • Arizona Hematology & Oncology Associates - Phoenix

Colorado

  • Rocky Mountain Cancer Centers - Aurora

Iowa

  • Iowa Oncology Associates - Cedar Rapids

Missouri

  • Oncology/Hematology Associates of Kansas City - Kansas City

North Carolina

  • Piedmont Hem Onc Assoc, P.A. - Winston-Salem

Ohio

  • Dayton Oncology/Hematology Consultants - Dayton

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2001-05
Est. Completion 2003-12
Phase Phase 2
Astellas Pharma

165 total trials

What the finished NCT00073489 record still lists

NCT00073489 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (87% lower).

The record links to 1 condition, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which OSI-461 is the first listed.

NCT00073489 lists 15 locations in 12 states (Texas, Florida, Arizona).

Frequently Asked Questions

What is clinical trial NCT00073489 about?

NCT00073489 is a clinical study titled "A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL)". The objectives of this study are to evaluate the safety and efficacy of OSI-461 in CLL patients.

What is the current status of trial NCT00073489?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2001-05. Estimated completion is 2003-12.

What conditions does trial NCT00073489 study?

This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia.

What interventions are being tested in trial NCT00073489?

The interventions under investigation include: OSI-461 (DRUG).

Who is sponsoring clinical trial NCT00073489?

This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00073489 being conducted?

This trial has 15 study locations across Arizona, Colorado, Florida, Iowa, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Lymphocytic Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00073489's enrollment target sits among peer trials

23 155th of 187 higher than 29 of 187 other Chronic Lymphocytic Leukemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Lymphocytic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03616041 · 23 participants

    Capsule Endoscopy for Severe Hematochezia

  • NCT04348747 · 23 participants · Phase 2

    Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

  • NCT04587687 · 23 participants · Phase 2

    Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

  • NCT04715022 · 23 participants · Phase 1

    Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00073489, the US trial registry maintained by the National Library of Medicine. NCT00073489 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.